Valuation: Novartis

Market Cap 295B 260B 241B 222B 416B 28,512B 423B 2,868B 1,120B 13,976B 1,108B 1,085B 48,367B P/E 2026 *
21.6x
P/E 2027 * 18.6x
Enterprise Value 328B 289B 269B 247B 463B 31,709B 471B 3,189B 1,245B 15,543B 1,233B 1,206B 53,791B EV / Sales 2026 *
5.71x
EV / Sales 2027 * 5.3x
Free-Float
91.66%
Yield 2026 *
2.81%
Yield 2027 * 2.94%
Manager TitleAgeSince
Chief Executive Officer 50 31/01/2018
Director of Finance/CFO - 15/03/2026
Chief Tech/Sci/R&D Officer 64 15/05/2022
Director TitleAgeSince
Director/Board Member 67 31/12/2014
Director/Board Member 69 31/12/2015
Director/Board Member 61 31/12/2015
Change 5-day change 1-year change 3-year change Capi.($)
+0.86%+2.30%+49.71%+158.86% 1,057B
+1.59%+5.37%+55.77%+54.77% 624B
+0.95%+1.95%+36.11%+80.44% 454B
+1.60%+7.09%+35.90%+29.32% 341B
-0.14%+0.33%+18.70%+17.64% 262B
+0.09%-4.53%-27.60%-42.19% 215B
+1.22%+1.20%+21.61%+60.14% 201B
-1.18%-5.13%+13.87%+60.35% 162B
-0.16%-2.39%-3.23%-34.39% 143B
Average +0.24%+0.32%+22.31%+42.77% 384.39B
Weighted average by Cap. +0.09%+1.31%+35.00%+75.49%

Financials

2026 *2027 *
Net sales 57.51B 50.61B 47.03B 43.18B 81.05B 5,553B 82.41B 559B 218B 2,722B 216B 211B 9,420B 60.99B 53.67B 49.87B 45.79B 85.95B 5,889B 87.39B 592B 231B 2,887B 229B 224B 9,990B
Net income 13.97B 12.29B 11.42B 10.49B 19.69B 1,349B 20.02B 136B 52.98B 661B 52.44B 51.31B 2,288B 15.64B 13.76B 12.79B 11.74B 22.03B 1,510B 22.4B 152B 59.3B 740B 58.69B 57.43B 2,561B
Net Debt 33.11B 29.14B 27.08B 24.86B 46.66B 3,197B 47.45B 322B 126B 1,567B 124B 122B 5,424B 27.82B 24.48B 22.75B 20.89B 39.2B 2,686B 39.86B 270B 105B 1,317B 104B 102B 4,556B
Logo Novartis
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA